HRTX icon

Heron Therapeutics

2.32 USD
-0.09
3.73%
At close Mar 13, 4:00 PM EDT
After hours
2.27
-0.05
2.16%
1 day
-3.73%
5 days
-2.11%
1 month
40.61%
3 months
45.00%
6 months
24.06%
Year to date
45.00%
1 year
-22.92%
5 years
-82.76%
10 years
-84.13%
 

About: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Employees: 122

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

7,109% more call options, than puts

Call options by funds: $4.61M | Put options by funds: $64K

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

4.88% less ownership

Funds ownership: 80.45% [Q3] → 75.58% (-4.88%) [Q4]

6% less funds holding

Funds holding: 172 [Q3] → 161 (-11) [Q4]

12% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 49

24% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 34

28% less capital invested

Capital invested by funds: $243M [Q3] → $176M (-$67M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$4
72%
upside
Avg. target
$4
72%
upside
High target
$4
72%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Needham
Serge Belanger
46% 1-year accuracy
55 / 120 met price target
72%upside
$4
Buy
Reiterated
28 Feb 2025

Financial journalist opinion

Based on 4 articles about HRTX published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Bill Forbes - Executive Vice President, Chief Development Officer Kevin Warner - Senior Vice President, Medical Affairs, Strategy and Engagement Conference Call Participants Brandon Folkes - Rodman & Renshaw Serge Belanger - Needham Carl Byrnes - Northland Capital Markets Clara Donald - Jefferies Operator Good day, and thank you for standing by, and welcome to the Heron Therapeutics Q4 2024 Conference Call. At this time, all participants are in a listen-only mode.
Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 weeks ago
Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Neutral
PRNewsWire
2 weeks ago
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Achieved Q4 2024 GAAP Net Income of $3.6 million Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year Delivered full-year 2024 adjusted EBITDA of $8.6 million Generated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024 U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA, LLC, and upheld the validity of CINVANTI® patents which expire in 2035  CARY, N.C. , Feb. 27, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2024, and highlighted recent corporate updates.
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Neutral
PRNewsWire
4 weeks ago
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
CARY, N.C., Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m.
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
Neutral
PRNewsWire
2 months ago
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majority of Heron's Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park ("RTP"), one of the most prominent high-tech research and development parks in the United States.
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Positive
Seeking Alpha
3 months ago
Relief For Heron Therapeutics After The Court Win On Cinvanti
Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on growing the business. Heron missed Q3 revenue estimates, but the company expects a recovery in Cinvanti sales in Q4 due to new account wins, and it shared encouraging trends of Zynrelef and Aponvie.
Relief For Heron Therapeutics After The Court Win On Cinvanti
Neutral
PRNewsWire
3 months ago
U.S. District Court Upholds Validity of CINVANTI® Patents
— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos.
U.S. District Court Upholds Validity of CINVANTI® Patents
Neutral
Seeking Alpha
4 months ago
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President & Chief Financial Officer William Forbes - Executive Vice President & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Serge Belanger - Needham Brandon Folkes - Rodman & Renshaw Operator Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
4 months ago
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Neutral
Zacks Investment Research
4 months ago
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Charts implemented using Lightweight Charts™